PT2153870E - Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática - Google Patents
Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática Download PDFInfo
- Publication number
- PT2153870E PT2153870E PT90136136T PT09013613T PT2153870E PT 2153870 E PT2153870 E PT 2153870E PT 90136136 T PT90136136 T PT 90136136T PT 09013613 T PT09013613 T PT 09013613T PT 2153870 E PT2153870 E PT 2153870E
- Authority
- PT
- Portugal
- Prior art keywords
- phenylbutyrate
- phenylacetate
- ornithine
- compositions
- hepatic encephalopathy
- Prior art date
Links
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 title abstract 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 title abstract 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 title abstract 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 title abstract 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003104 ornithine Drugs 0.000 title abstract 3
- 229940049953 phenylacetate Drugs 0.000 title abstract 3
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title abstract 3
- 229950009215 phenylbutanoic acid Drugs 0.000 title abstract 3
- 208000007386 hepatic encephalopathy Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010020575 Hyperammonaemia Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0426142A GB0426142D0 (en) | 2004-11-26 | 2004-11-26 | Formulation |
| GB0426141A GB0426141D0 (en) | 2004-11-26 | 2004-11-26 | Treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2153870E true PT2153870E (pt) | 2014-03-12 |
Family
ID=35559327
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT90136136T PT2153870E (pt) | 2004-11-26 | 2005-11-28 | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| PT100142835T PT2319581E (pt) | 2004-11-26 | 2005-11-28 | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| PT05808837T PT1824563E (pt) | 2004-11-26 | 2005-11-28 | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT100142835T PT2319581E (pt) | 2004-11-26 | 2005-11-28 | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| PT05808837T PT1824563E (pt) | 2004-11-26 | 2005-11-28 | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8389576B2 (pt) |
| EP (3) | EP1824563B1 (pt) |
| JP (2) | JP5116479B2 (pt) |
| KR (1) | KR101380446B1 (pt) |
| CN (1) | CN102512408B (pt) |
| AT (1) | ATE457187T1 (pt) |
| AU (1) | AU2005308622B2 (pt) |
| CA (1) | CA2589261C (pt) |
| CY (3) | CY1112259T1 (pt) |
| DE (1) | DE602005019319D1 (pt) |
| DK (3) | DK2153870T3 (pt) |
| EA (2) | EA011716B1 (pt) |
| ES (3) | ES2341120T3 (pt) |
| HK (1) | HK1141471A1 (pt) |
| IL (1) | IL183401A (pt) |
| MX (1) | MX2007006171A (pt) |
| NO (2) | NO342198B1 (pt) |
| NZ (1) | NZ555870A (pt) |
| PL (3) | PL1824563T3 (pt) |
| PT (3) | PT2153870E (pt) |
| SG (1) | SG158073A1 (pt) |
| SI (3) | SI2319581T1 (pt) |
| WO (1) | WO2006056794A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011716B1 (ru) * | 2004-11-26 | 2009-04-28 | Ю Си Эл БИЗНЕС Пи Эл Си | Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии |
| EP3133396B1 (en) * | 2008-04-29 | 2018-09-05 | Horizon Therapeutics, LLC | Methods of treatment using ammonia-scavenging drugs |
| EP2338050A1 (en) * | 2008-08-29 | 2011-06-29 | Ucyclyd Pharma, Inc. | Dosing and monitoring patients on nitrogen-scavenging drugs |
| US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| PL3628319T3 (pl) | 2008-10-02 | 2024-04-29 | Salix Pharmaceuticals, Ltd. | Leczenie encefalopatii wątrobowej za pomocą ryfaksyminy |
| EP2413924B1 (en) | 2009-04-03 | 2017-09-27 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| NZ615091A (en) * | 2009-06-08 | 2015-03-27 | Ucl Business Plc | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
| EP2397458A1 (en) * | 2010-06-21 | 2011-12-21 | Lunamed AG | Organic salts and co-crystals of phenylbutyric acid |
| SG189231A1 (en) | 2010-10-06 | 2013-05-31 | Ocera Therapeutics Inc | Methods of making l-ornithine phenyl acetate |
| PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
| EP3222275B1 (en) | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
| CA2891657A1 (en) | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US20150094278A1 (en) * | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| LT3099306T (lt) | 2014-01-29 | 2019-03-12 | Umecrine Cognition Ab | Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui |
| US10039735B2 (en) * | 2014-11-24 | 2018-08-07 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| ES2944311T3 (es) * | 2015-04-20 | 2023-06-20 | Ocera Therapeutics Inc | Formulaciones de fenilacetato de L-ornitina |
| EP3337473A4 (en) * | 2015-08-18 | 2019-04-17 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
| AU2016325556B2 (en) * | 2015-09-25 | 2023-02-16 | Ocera Therapeutics, Inc. | Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| WO2017083758A1 (en) * | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulation of l-ornithine phenylacetate |
| WO2017090007A1 (en) * | 2015-11-29 | 2017-06-01 | Rao M Surya | Compositions and methods for the treatment of urea cycle disorders and hepatic diseases |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| US11066352B2 (en) | 2017-05-11 | 2021-07-20 | Ocera Therapeutics, Inc. | Processes of making L-ornithine phenylacetate |
| WO2018225167A1 (ja) | 2017-06-07 | 2018-12-13 | 花王株式会社 | アンモニア代謝促進剤 |
| CN110709072A (zh) * | 2017-06-07 | 2020-01-17 | 花王株式会社 | 氨代谢促进剂 |
| US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| JP7197340B2 (ja) * | 2018-12-06 | 2022-12-27 | 花王株式会社 | 認知機能改善剤 |
| CN113713817B (zh) * | 2020-05-26 | 2023-06-27 | 中国科学院大连化学物理研究所 | 一种采用镍基催化剂催化丙醛加氢制正丙醇的方法 |
| BR112023010517A2 (pt) * | 2020-12-01 | 2024-02-06 | Wellstat Therapeutics Corp | 5'-o-fenilacetil uridina e seu uso terapêutico |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE380814A (pt) * | 1930-06-26 | |||
| US1980422A (en) * | 1931-09-30 | 1934-11-13 | Mesick John | Plotting board |
| US2271378A (en) * | 1939-08-30 | 1942-01-27 | Du Pont | Pest control |
| US2273780A (en) * | 1939-12-30 | 1942-02-17 | Du Pont | Wax acryalte ester blends |
| US2261002A (en) * | 1941-06-17 | 1941-10-28 | Du Pont | Organic nitrogen compounds |
| US2388614A (en) * | 1942-05-05 | 1945-11-06 | Du Pont | Disinfectant compositions |
| US2375853A (en) * | 1942-10-07 | 1945-05-15 | Du Pont | Diamine derivatives |
| US2454547A (en) * | 1946-10-15 | 1948-11-23 | Rohm & Haas | Polymeric quaternary ammonium salts |
| US2723248A (en) * | 1954-10-01 | 1955-11-08 | Gen Aniline & Film Corp | Film-forming compositions |
| US2961347A (en) * | 1957-11-13 | 1960-11-22 | Hercules Powder Co Ltd | Process for preventing shrinkage and felting of wool |
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| US3227615A (en) * | 1962-05-29 | 1966-01-04 | Hercules Powder Co Ltd | Process and composition for the permanent waving of hair |
| US3206462A (en) * | 1962-10-31 | 1965-09-14 | Dow Chemical Co | Quaternary poly(oxyalkylene)alkylbis(diethylenetriamine) compounds |
| NL302572A (pt) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| US3256154A (en) * | 1963-10-18 | 1966-06-14 | Gillette Co | Hair waving composition and method |
| FR1517743A (fr) * | 1966-08-03 | 1968-03-22 | Oreal | Nouveaux copolymères et compositions cosmétiques contenant ces copolymères |
| US3472840A (en) * | 1965-09-14 | 1969-10-14 | Union Carbide Corp | Quaternary nitrogen-containing cellulose ethers |
| US3810977A (en) * | 1967-03-23 | 1974-05-14 | Nat Starch Chem Corp | Hair fixing composition and process containing a solid terpolymer |
| CH491153A (de) * | 1967-09-28 | 1970-05-31 | Sandoz Ag | Verfahren zur Herstellung von neuen kationaktiven, wasserlöslichen Polyamiden |
| US3836537A (en) * | 1970-10-07 | 1974-09-17 | Minnesota Mining & Mfg | Zwitterionic polymer hairsetting compositions and method of using same |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| LU64371A1 (pt) * | 1971-11-29 | 1973-06-21 | ||
| US4013787A (en) * | 1971-11-29 | 1977-03-22 | Societe Anonyme Dite: L'oreal | Piperazine based polymer and hair treating composition containing the same |
| LU65552A1 (pt) * | 1972-06-20 | 1973-12-27 | ||
| CA981746A (en) * | 1973-09-24 | 1976-01-13 | Alfred M. Hase | Battery charging circuit |
| US4172887A (en) * | 1973-11-30 | 1979-10-30 | L'oreal | Hair conditioning compositions containing crosslinked polyaminopolyamides |
| US4277581A (en) * | 1973-11-30 | 1981-07-07 | L'oreal | Polyamino-polyamide crosslinked with crosslinking agent |
| US4189468A (en) * | 1973-11-30 | 1980-02-19 | L'oreal | Crosslinked polyamino-polyamide in hair conditioning compositions |
| US3874870A (en) * | 1973-12-18 | 1975-04-01 | Mill Master Onyx Corp | Microbiocidal polymeric quarternary ammonium compounds |
| US3929990A (en) * | 1973-12-18 | 1975-12-30 | Millmaster Onyx Corp | Microbiocidal polymeric quaternary ammonium compounds |
| US4025627A (en) * | 1973-12-18 | 1977-05-24 | Millmaster Onyx Corporation | Microbiocidal polymeric quaternary ammonium compounds |
| US4166894A (en) * | 1974-01-25 | 1979-09-04 | Calgon Corporation | Functional ionene compositions and their use |
| DK659674A (pt) * | 1974-01-25 | 1975-09-29 | Calgon Corp | |
| LU69759A1 (pt) * | 1974-04-01 | 1976-03-17 | ||
| LU69760A1 (pt) * | 1974-04-01 | 1976-03-17 | ||
| US4100293A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US4217914A (en) * | 1974-05-16 | 1980-08-19 | L'oreal | Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin |
| US4948579A (en) * | 1974-05-16 | 1990-08-14 | Societe Anonyme Dite: L'oreal | Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin |
| US5196189A (en) * | 1974-05-16 | 1993-03-23 | Societe Anonyme Dite: L'oreal | Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin |
| US4422853A (en) * | 1974-05-16 | 1983-12-27 | L'oreal | Hair dyeing compositions containing quaternized polymer |
| US4005193A (en) * | 1974-08-07 | 1977-01-25 | Millmaster Onyx Corporation | Microbiocidal polymeric quaternary ammonium compounds |
| US3966904A (en) * | 1974-10-03 | 1976-06-29 | Millmaster Onyx Corporation | Quaternary ammonium co-polymers for controlling the proliferation of bacteria |
| US4025617A (en) * | 1974-10-03 | 1977-05-24 | Millmaster Onyx Corporation | Anti-microbial quaternary ammonium co-polymers |
| US4026945A (en) * | 1974-10-03 | 1977-05-31 | Millmaster Onyx Corporation | Anti-microbial quaternary ammonium co-polymers |
| US4027020A (en) * | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US4001432A (en) * | 1974-10-29 | 1977-01-04 | Millmaster Onyx Corporation | Method of inhibiting the growth of bacteria by the application thereto of capped polymers |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4025653A (en) * | 1975-04-07 | 1977-05-24 | Millmaster Onyx Corporation | Microbiocidal polymeric quaternary ammonium compounds |
| AT365448B (de) * | 1975-07-04 | 1982-01-11 | Oreal | Kosmetische zubereitung |
| US4197865A (en) * | 1975-07-04 | 1980-04-15 | L'oreal | Treating hair with quaternized polymers |
| IT1082729B (it) * | 1976-04-06 | 1985-05-21 | Oreal | Copolimeri acrilici e composizioni cosmetiche contenenti tali copolimeri |
| US4031307A (en) * | 1976-05-03 | 1977-06-21 | Celanese Corporation | Cationic polygalactomannan compositions |
| GB1572837A (en) * | 1976-05-06 | 1980-08-06 | Berger Jenson & Nicholson Ltd | Coating composition |
| US4128631A (en) * | 1977-02-16 | 1978-12-05 | General Mills Chemicals, Inc. | Method of imparting lubricity to keratinous substrates and mucous membranes |
| LU78153A1 (fr) * | 1977-09-20 | 1979-05-25 | Oreal | Compositions cosmetiques a base de polymeres polyammonium quaternaires et procede de preparation |
| US4131576A (en) * | 1977-12-15 | 1978-12-26 | National Starch And Chemical Corporation | Process for the preparation of graft copolymers of a water soluble monomer and polysaccharide employing a two-phase reaction system |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4348202A (en) * | 1978-06-15 | 1982-09-07 | L'oreal | Hair dye or bleach supports |
| US4970066A (en) * | 1978-06-15 | 1990-11-13 | L'oreal | Hair dye or bleach supports of quaternized polymers |
| FR2439798A1 (fr) * | 1978-10-27 | 1980-05-23 | Oreal | Nouveaux copolymeres utilisables en cosmetique, notamment dans des laques et lotions de mises en plis |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| LU83349A1 (fr) * | 1981-05-08 | 1983-03-24 | Oreal | Composition sous forme de mousse aerosol a base de polymere cationique et de polymere anionique |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| LU84463A1 (fr) * | 1982-11-10 | 1984-06-13 | Oreal | Polymeres polysiloxanes polyquaternaires |
| LU84708A1 (fr) * | 1983-03-23 | 1984-11-14 | Oreal | Composition epaissie ou gelifiee de conditionnement des cheveux contenant au moins un polymere cationique,au moins un polymere anionique et au moins une gomme de xanthane |
| US4812307A (en) * | 1983-07-06 | 1989-03-14 | Chesebrough-Pond's Inc. | Crosslinking of hair thiols using glutathione disulfide |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| EP0269107A3 (en) * | 1986-11-28 | 1989-10-11 | Kao Corporation | Composition for hair treatment agent |
| US4749732A (en) * | 1987-01-02 | 1988-06-07 | Dow Corning Corporation | Hair care composition containing modified aminoalkyl substituted polydiorganosiloxane |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| US4795629A (en) * | 1987-07-06 | 1989-01-03 | Chesebrough-Pond's Inc. | Crosslinking of hair thiols using cystamine |
| LU87310A1 (fr) * | 1988-08-04 | 1990-03-13 | Oreal | N-(mercaptoalkyl)omega-hydroxyalkylamides et leur utilisation en tant qu'agents reducteurs,dans un procede de deformation permanente des cheveux |
| FR2654617B1 (fr) * | 1989-11-20 | 1993-10-08 | Oreal | Composition cosmetique reductrice pour permanente contenant, en tant qu'agent reducteur, de l'aletheine ou l'un de ses sels, et son utilisation dans un procede de deformation permanente des cheveux. |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| DE4020980C1 (pt) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| JP3127484B2 (ja) * | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| FR2676441B1 (fr) * | 1991-05-17 | 1994-10-28 | Oreal | Nouveaux alkylamino-mercaptoalkylamides ou l'un de leurs sels cosmetiquement acceptables, et leur utilisation en tant qu'agents reducteurs, dans un procede de deformation permanente des cheveux. |
| FR2677543B1 (fr) * | 1991-06-13 | 1993-09-24 | Oreal | Composition cosmetique filtrante a base d'acide benzene 1,4-di(3-methylidene-10-camphosulfonique) et de nanopigments d'oxydes metalliques. |
| US5767086A (en) * | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US6083953A (en) | 1994-07-28 | 2000-07-04 | Syntex (U.S.A.) Inc. | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| AU2251897A (en) | 1996-02-13 | 1997-09-02 | Trustees Of The University Of Pennsylvania, The | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| WO2000071151A1 (fr) | 1999-05-21 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Regulateurs des fonctions hepatiques |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| ATE441409T1 (de) | 2001-03-15 | 2009-09-15 | Riken | Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| CN1383815A (zh) * | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| AU2003261825A1 (en) | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1744770A2 (en) | 2004-05-06 | 2007-01-24 | Osteologix A/S | High yield and rapid syntheses methods for producing metallo-organic salts |
| EP1799759A1 (en) | 2004-08-30 | 2007-06-27 | Lunamed Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| EA011716B1 (ru) | 2004-11-26 | 2009-04-28 | Ю Си Эл БИЗНЕС Пи Эл Си | Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии |
| GB0426141D0 (en) | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| JP5221858B2 (ja) | 2006-08-30 | 2013-06-26 | 株式会社日立ハイテクノロジーズ | 欠陥検査装置、及び欠陥検査方法 |
| EP2413924B1 (en) | 2009-04-03 | 2017-09-27 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| NZ615091A (en) | 2009-06-08 | 2015-03-27 | Ucl Business Plc | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| SG189231A1 (en) | 2010-10-06 | 2013-05-31 | Ocera Therapeutics Inc | Methods of making l-ornithine phenyl acetate |
| ES2944311T3 (es) | 2015-04-20 | 2023-06-20 | Ocera Therapeutics Inc | Formulaciones de fenilacetato de L-ornitina |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
-
2005
- 2005-11-28 EA EA200701146A patent/EA011716B1/ru unknown
- 2005-11-28 CN CN201110304561.7A patent/CN102512408B/zh active Active
- 2005-11-28 PL PL05808837T patent/PL1824563T3/pl unknown
- 2005-11-28 SI SI200531970T patent/SI2319581T1/sl unknown
- 2005-11-28 AU AU2005308622A patent/AU2005308622B2/en not_active Ceased
- 2005-11-28 SI SI200531834T patent/SI2153870T1/sl unknown
- 2005-11-28 SI SI200530993T patent/SI1824563T1/sl unknown
- 2005-11-28 KR KR1020077014477A patent/KR101380446B1/ko active IP Right Grant
- 2005-11-28 CA CA2589261A patent/CA2589261C/en active Active
- 2005-11-28 SG SG200907712-4A patent/SG158073A1/en unknown
- 2005-11-28 PL PL09013613T patent/PL2153870T3/pl unknown
- 2005-11-28 ES ES05808837T patent/ES2341120T3/es active Active
- 2005-11-28 US US11/720,268 patent/US8389576B2/en active Active
- 2005-11-28 EA EA200900105A patent/EA018007B1/ru unknown
- 2005-11-28 NZ NZ555870A patent/NZ555870A/en unknown
- 2005-11-28 PT PT90136136T patent/PT2153870E/pt unknown
- 2005-11-28 DK DK09013613.6T patent/DK2153870T3/en active
- 2005-11-28 ES ES10014283.5T patent/ES2537974T3/es active Active
- 2005-11-28 DK DK10014283.5T patent/DK2319581T3/en active
- 2005-11-28 JP JP2007542118A patent/JP5116479B2/ja active Active
- 2005-11-28 ES ES09013613.6T patent/ES2448549T3/es active Active
- 2005-11-28 AT AT05808837T patent/ATE457187T1/de active
- 2005-11-28 EP EP05808837A patent/EP1824563B1/en active Active
- 2005-11-28 WO PCT/GB2005/004539 patent/WO2006056794A1/en active Application Filing
- 2005-11-28 PT PT100142835T patent/PT2319581E/pt unknown
- 2005-11-28 EP EP09013613.6A patent/EP2153870B1/en active Active
- 2005-11-28 DK DK05808837.8T patent/DK1824563T3/da active
- 2005-11-28 PL PL10014283T patent/PL2319581T3/pl unknown
- 2005-11-28 PT PT05808837T patent/PT1824563E/pt unknown
- 2005-11-28 DE DE602005019319T patent/DE602005019319D1/de active Active
- 2005-11-28 EP EP10014283.5A patent/EP2319581B1/en active Active
- 2005-11-28 MX MX2007006171A patent/MX2007006171A/es active IP Right Grant
-
2007
- 2007-05-24 IL IL183401A patent/IL183401A/en active IP Right Grant
- 2007-06-25 NO NO20073254A patent/NO342198B1/no unknown
-
2010
- 2010-05-07 CY CY20101100397T patent/CY1112259T1/el unknown
- 2010-08-16 HK HK10107783.4A patent/HK1141471A1/xx unknown
-
2012
- 2012-06-13 US US13/495,966 patent/US9566257B2/en active Active
- 2012-07-13 JP JP2012157179A patent/JP5612030B2/ja active Active
-
2014
- 2014-03-18 CY CY20141100215T patent/CY1114979T1/el unknown
-
2015
- 2015-05-25 CY CY20151100464T patent/CY1116314T1/el unknown
-
2016
- 2016-11-16 NO NO20161808A patent/NO341491B1/no unknown
-
2017
- 2017-02-10 US US15/430,233 patent/US10610506B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1141471A1 (en) | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | |
| NZ596916A (en) | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate | |
| WO2006068729A3 (en) | Methods and compositions for enhancing iron absorption | |
| HK1124552A1 (en) | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases | |
| WO2006116177A3 (en) | Mouth guard | |
| EP1774968A4 (en) | BENZYLISOQUINOLEIN DERIVATIVE OR BISBENZYLISOQUINOLEIN DERIVATIVE - CONTAINING PSYCHOTROPIC, ANALGESIC AND / OR ANTIPHLOGISTIC AGENT, AND HEALTH FOOD. | |
| WO2010036395A3 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
| MY148459A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
| WO2007084857A3 (en) | Methods and compositions for treating cell proliferative disorders | |
| WO2010062581A3 (en) | A botanical composition for enhanced skin repair and uses thereof | |
| EP2183084A4 (en) | SAW CHAIN FOR CUTTING AGGREGATES | |
| WO2007146983A3 (en) | Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury | |
| BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
| MX2010001243A (es) | Composicion anti-inflamatoria. | |
| PL1703901T3 (pl) | Farmaceutyczna kompozycja zawierająca alkohol 2,4-dichlorobenzylowy i amylometakrezol | |
| WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder | |
| ATE258435T1 (de) | Pinolensäure gegen diabetes | |
| TNSN07364A1 (en) | Use of agomelatine for obtaining medicaments used for treating bipolar disorders | |
| UA35751U (ru) | Применение препарата "кристалл-900" в виде дезинфицирующего средства в рыбоводстве | |
| AU2007904328A0 (en) | The use of poloxamer 407 and other agents acting on the liver sinusoidal endothelial cell for treatment and prevention of chemical-induced liver injury including paracetamol overdose | |
| GEU20071328Y (en) | Intrastromal cornea arch |